NDA 218614 · Ionis Pharms INC
Tryngolza (Autoinjector)
Olezarsen Sodium · Subcutaneous
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Dec 19, 2024: To treat familial chylomicronemia syndrome
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 19, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
8 Phase 3, 1 recruiting
FAERS reports
947
201 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 3, 2026.
TRYNGOLZA ® is indicated as an adjunct to diet: To reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). To reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). TRYNGOLZA is an apolipoprotein C-III (apoC-III)-directed antisense oligonucleotide (ASO) indicated as an adjunct to diet: To reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). ( 1 ) To reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). ( 1 )
Mechanism: Olezarsen is an ASO-GalNAc 3 conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein. Reduction of apoC-III protein leads to increased clearance of plasma TG and very low-density lipoprotein (VLDL).
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 2026 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Dec 19, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- TRYNGOLZA (AUTOINJECTOR) · OLEZARSEN SODIUM EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
- TRYNGOLZA (AUTOINJECTOR) · OLEZARSEN SODIUM EQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olezarsen" as an intervention, any sponsor and status, largest first.
- A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaPivotal-lookingCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05610280 · 1,478 participants · Start Nov 21, 2022 · Primary completion Aug 8, 2024
Drug: Olezarsen; Placebo · For: Hypertriglyceridemia; Cardiovascular Diseases; Atherosclerosis
Sites: Birmingham, Alabama; Huntsville, Alabama; Beverly Hills, California · 168 sites in all
- CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)Pivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05681351 · 885 participants · Start Dec 13, 2022 · Primary completion Mar 2027
Drug: Olezarsen · For: Severe Hypertriglyceridemia
Sites: Los Angeles, California; San Diego, California; Tarzana, California · 262 sites in all
- A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe HypertriglyceridemiaPivotal-lookingCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05079919 · 617 participants · Start Oct 25, 2021 · Primary completion Oct 22, 2024
Drug: Olezarsen; Placebo · For: Severe Hypertriglyceridemia
Sites: Birmingham, Alabama; Scottsdale, Arizona; Chula Vista, California · 209 sites in all
- A Study of Olezarsen Administered Subcutaneously to Participants With Severe HypertriglyceridemiaPivotal-lookingCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05552326 · 446 participants · Start Aug 31, 2022 · Primary completion Dec 17, 2024
Drug: Olezarsen; Placebo · For: Severe Hypertriglyceridemia
Sites: Birmingham, Alabama; Peoria, Arizona; Los Angeles, California · 205 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05355402 · 154 participants · Start May 9, 2022 · Primary completion Mar 22, 2023
Drug: Olezarsen; Placebo · For: Hypertriglyceridemia; Atherosclerotic Cardiovascular Disease; Severe Hypertriglyceridemia
Sites: Lincoln, California; Montclair, California; Boca Raton, Florida · 24 sites in all
- A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult ParticipantsPivotal-lookingCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05579860 · 104 participants · Start Oct 5, 2022 · Primary completion May 22, 2023
Drug: Olezarsen · For: Healthy Participants
Sites: Cincinnati, Ohio
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)Pivotal-lookingCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04568434 · 66 participants · Start Nov 18, 2020 · Primary completion Jul 14, 2023
Drug: Olezarsen; Placebo · For: Familial Chylomicronemia Syndrome
Sites: Huntington Beach, California; San Francisco, California; Boca Raton, Florida · 47 sites in all
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)Pivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05130450 · 60 participants · Start Nov 18, 2021 · Primary completion Feb 2028
Drug: Olezarsen · For: Familial Chylomicronemia Syndrome
Sites: Huntington Beach, California; Boca Raton, Florida; Park Ridge, Illinois · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain84
- blood triglycerides increased82
- injection site erythema77
- product dose omission issue63
- off label use57
- arthralgia40
- nausea36
- pancreatitis35
- pancreatitis acute34
- injection site swelling33
- fatigue30
- injection site rash30
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 152 |
| 2026 | 795 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
Marston NA, Bergmark BA, Alexander VJ, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Multicenter Study
- Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
Bergmark BA, Marston NA, Prohaska TA, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA, Marston NA, Prohaska TA, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome.
Yang X, Alexander VJ, Xia S, et al. · Atherosclerosis 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effect of olezarsen on routinely measured lipase and amylase levels in familial chylomicronemia syndrome.
Alexander VJ, Prohaska TA, Karwatowska-Prokopczuk E, et al. · J Clin Lipidol 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Ionis Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.